{"pmid":32237249,"title":"Quarantined.","text":["Quarantined.","As an emergency medicine physician, I am used to working when most people are not working. At the end of February, the first patient in the U.S. to be diagnosed with COVID-19 without a travel history occurred in Sacramento, CA. Over 120 healthcare professionals who had contact with the patient were quarantined. Beginning of March, I worked in the emergency department and treated a patient with viral symptoms without a travel history who was admitted to the hospital.","Acad Emerg Med","Lee, Moon","32237249"],"abstract":["As an emergency medicine physician, I am used to working when most people are not working. At the end of February, the first patient in the U.S. to be diagnosed with COVID-19 without a travel history occurred in Sacramento, CA. Over 120 healthcare professionals who had contact with the patient were quarantined. Beginning of March, I worked in the emergency department and treated a patient with viral symptoms without a travel history who was admitted to the hospital."],"journal":"Acad Emerg Med","authors":["Lee, Moon"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32237249","week":"202014|Mar 30 - Apr 05","doi":"10.1111/acem.13975","source":"PubMed","locations":["USA","Sacramento"],"countries":["United States"],"countries_codes":["USA|United States"],"weight":0,"_version_":1662996001907015681,"score":7.6048946,"similar":[{"pmid":32134861,"title":"The outbreak of COVID-19: An overview.","text":["The outbreak of COVID-19: An overview.","In late December 2019, a previous unidentified coronavirus, currently named as the 2019 novel coronavirus#, emerged from Wuhan, China, and resulted in a formidable outbreak in many cities in China and expanded globally, including Thailand, Republic of Korea, Japan, United States, Philippines, Viet Nam, and our country (as of 2/6/2020 at least 25 countries). The disease is officially named as Coronavirus Disease-2019 (COVID-19, by WHO on February 11, 2020). It is also named as Severe Pneumonia with Novel Pathogens on January 15, 2019 by the Taiwan CDC, the Ministry of Health and is a notifiable communicable disease of the fifth category. COVID-19 is a potential zoonotic disease with low to moderate (estimated 2%-5%) mortality rate. Person-to-person transmission may occur through droplet or contact transmission and if there is a lack of stringent infection control or if no proper personal protective equipment available, it may jeopardize the first-line healthcare workers. Currently, there is no definite treatment for COVID-19 although some drugs are under investigation. To promptly identify patients and prevent further spreading, physicians should be aware of the travel or contact history of the patient with compatible symptoms.","J Chin Med Assoc","Wu, Yi-Chi","Chen, Ching-Sung","Chan, Yu-Jiun","32134861"],"abstract":["In late December 2019, a previous unidentified coronavirus, currently named as the 2019 novel coronavirus#, emerged from Wuhan, China, and resulted in a formidable outbreak in many cities in China and expanded globally, including Thailand, Republic of Korea, Japan, United States, Philippines, Viet Nam, and our country (as of 2/6/2020 at least 25 countries). The disease is officially named as Coronavirus Disease-2019 (COVID-19, by WHO on February 11, 2020). It is also named as Severe Pneumonia with Novel Pathogens on January 15, 2019 by the Taiwan CDC, the Ministry of Health and is a notifiable communicable disease of the fifth category. COVID-19 is a potential zoonotic disease with low to moderate (estimated 2%-5%) mortality rate. Person-to-person transmission may occur through droplet or contact transmission and if there is a lack of stringent infection control or if no proper personal protective equipment available, it may jeopardize the first-line healthcare workers. Currently, there is no definite treatment for COVID-19 although some drugs are under investigation. To promptly identify patients and prevent further spreading, physicians should be aware of the travel or contact history of the patient with compatible symptoms."],"journal":"J Chin Med Assoc","authors":["Wu, Yi-Chi","Chen, Ching-Sung","Chan, Yu-Jiun"],"date":"2020-03-06T11:00:00Z","year":2020,"_id":"32134861","week":"202010|Mar 02 - Mar 08","doi":"10.1097/JCMA.0000000000000270","source":"PubMed","locations":["Thailand","South Korea","Japan","Viet Nam","China","Wuhan","United States","Philippines"],"countries":["Thailand","China","Philippines","Korea, Republic of","Viet Nam","Japan","United States"],"countries_codes":["THA|Thailand","CHN|China","PHL|Philippines","KOR|Korea, Republic of","VNM|Viet Nam","JPN|Japan","USA|United States"],"topics":["Diagnosis","Prevention"],"weight":1,"_version_":1662334543970959360,"score":70.575264},{"pmid":32049687,"title":"Overview of The 2019 Novel Coronavirus (2019-nCoV): The Pathogen of Severe Specific Contagious Pneumonia (SSCP).","text":["Overview of The 2019 Novel Coronavirus (2019-nCoV): The Pathogen of Severe Specific Contagious Pneumonia (SSCP).","In late December 2019 a previous unidentified coronavirus, currently named as the 2019 novel coronavirus (2019-nCoV), emerged from Wuhan, China and resulted in a formidable outbreak in many cities in China and expanding globally, including Thailand, Republic of Korea, Japan, USA, Philippines, Viet Nam, and our country (as of 2/6/2020 at least 25 countries). The disease is officially named as the Severe Specific Contagious Pneumonia (SSCP) in 1/15/2019 and is a notifiable communicable disease of the 5 category by the Taiwan CDC, the Ministry of Health. SSCP is a potential zoonotic disease with low to moderate (estimated 2-5%) mortality rate. Person-to-person transmission may occur through droplet or contact transmission and jeopardized first-line healthcare workers if lack of stringent infection control or no proper personal protective equipment available. Currently, there is no definite treatment for SSCP although some drugs are under investigation. To promptly identify patients and prevent further spreading, physicians should be aware of travel or contact history for patients with compatible symptoms.","J Chin Med Assoc","Wu, Yi-Chi","Chen, Ching-Sung","Chan, Yu-Jiun","32049687"],"abstract":["In late December 2019 a previous unidentified coronavirus, currently named as the 2019 novel coronavirus (2019-nCoV), emerged from Wuhan, China and resulted in a formidable outbreak in many cities in China and expanding globally, including Thailand, Republic of Korea, Japan, USA, Philippines, Viet Nam, and our country (as of 2/6/2020 at least 25 countries). The disease is officially named as the Severe Specific Contagious Pneumonia (SSCP) in 1/15/2019 and is a notifiable communicable disease of the 5 category by the Taiwan CDC, the Ministry of Health. SSCP is a potential zoonotic disease with low to moderate (estimated 2-5%) mortality rate. Person-to-person transmission may occur through droplet or contact transmission and jeopardized first-line healthcare workers if lack of stringent infection control or no proper personal protective equipment available. Currently, there is no definite treatment for SSCP although some drugs are under investigation. To promptly identify patients and prevent further spreading, physicians should be aware of travel or contact history for patients with compatible symptoms."],"journal":"J Chin Med Assoc","authors":["Wu, Yi-Chi","Chen, Ching-Sung","Chan, Yu-Jiun"],"date":"2020-02-13T11:00:00Z","year":2020,"_id":"32049687","week":"20207|Feb 10 - Feb 16","doi":"10.1097/JCMA.0000000000000270","source":"PubMed","locations":["China","Japan","USA","Thailand","Viet Nam","Wuhan","South Korea","Philippines"],"countries":["Japan","China","Viet Nam","United States","Thailand","Korea, Republic of","Philippines"],"countries_codes":["JPN|Japan","CHN|China","VNM|Viet Nam","USA|United States","THA|Thailand","KOR|Korea, Republic of","PHL|Philippines"],"topics":["Diagnosis","Prevention"],"weight":1,"_version_":1663095626224631810,"score":69.41693},{"pmid":32091395,"pmcid":"PMC7060038","title":"Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19.","text":["Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19.","Traveller screening is being used to limit further spread of COVID-19 following its recent emergence, and symptom screening has become a ubiquitous tool in the global response. Previously, we developed a mathematical model to understand factors governing the effectiveness of traveller screening to prevent spread of emerging pathogens (Gostic et al., 2015). Here, we estimate the impact of different screening programs given current knowledge of key COVID-19 life history and epidemiological parameters. Even under best-case assumptions, we estimate that screening will miss more than half of infected people. Breaking down the factors leading to screening successes and failures, we find that most cases missed by screening are fundamentally undetectable, because they have not yet developed symptoms and are unaware they were exposed. Our work underscores the need for measures to limit transmission by individuals who become ill after being missed by a screening program. These findings can support evidence-based policy to combat the spread of COVID-19, and prospective planning to mitigate future emerging pathogens.","Elife","Gostic, Katelyn","Gomez, Ana Cr","Mummah, Riley O","Kucharski, Adam J","Lloyd-Smith, James O","32091395"],"abstract":["Traveller screening is being used to limit further spread of COVID-19 following its recent emergence, and symptom screening has become a ubiquitous tool in the global response. Previously, we developed a mathematical model to understand factors governing the effectiveness of traveller screening to prevent spread of emerging pathogens (Gostic et al., 2015). Here, we estimate the impact of different screening programs given current knowledge of key COVID-19 life history and epidemiological parameters. Even under best-case assumptions, we estimate that screening will miss more than half of infected people. Breaking down the factors leading to screening successes and failures, we find that most cases missed by screening are fundamentally undetectable, because they have not yet developed symptoms and are unaware they were exposed. Our work underscores the need for measures to limit transmission by individuals who become ill after being missed by a screening program. These findings can support evidence-based policy to combat the spread of COVID-19, and prospective planning to mitigate future emerging pathogens."],"journal":"Elife","authors":["Gostic, Katelyn","Gomez, Ana Cr","Mummah, Riley O","Kucharski, Adam J","Lloyd-Smith, James O"],"date":"2020-02-25T11:00:00Z","year":2020,"_id":"32091395","week":"20209|Feb 24 - Mar 01","doi":"10.7554/eLife.55570","keywords":["*COVID-19","*SARS-CoV-2","*emerging infectious disease","*epidemic containment","*epidemic control","*epidemiology","*global health","*human","*travel screening","*virus"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1662334544327475200,"score":66.46444},{"pmid":32223774,"title":"Roadblocks to Infection Prevention Efforts in Healthcare SARS-CoV-2/COVID-19 Response.","text":["Roadblocks to Infection Prevention Efforts in Healthcare SARS-CoV-2/COVID-19 Response.","The outbreak of a novel coronavirus, COVID-19, is challenging international public health and healthcare efforts. As hospitals work to acquire enough personal protective equipment and brace for potential cases, the role of infection prevention efforts and programs has become increasingly important. Lessons from the 2003 SARS-CoV outbreak in Toronto and 2015 MERS-CoV outbreak in South Korea have unveiled the critical role that hospitals play in outbreaks, especially of novel coronaviruses. Their ability to amplify the spread of disease can rapidly fuel transmission of the disease and often those failures in infection prevention and general hospital practices contribute to such events. While efforts to enhance infection prevention measures and hospital readiness are underway in the United States, it is important to understand why these programs were not able to maintain continued, sustainable levels of readiness. History has shown that infection prevention programs are primarily responsible for preparing hospitals and responding to biological events but face under-staffing and focused efforts defined by administrators. The current U.S. healthcare system though, is built upon a series of priorities that often view biopreparedness as a costly endeavor. Awareness of these competing priorities and the challenges infection prevention programs face when working to maintain biopreparedness is critical in adequately addressing this critical infrastructure in the face of an international outbreak.","Disaster Med Public Health Prep","Popescu, Saskia","32223774"],"abstract":["The outbreak of a novel coronavirus, COVID-19, is challenging international public health and healthcare efforts. As hospitals work to acquire enough personal protective equipment and brace for potential cases, the role of infection prevention efforts and programs has become increasingly important. Lessons from the 2003 SARS-CoV outbreak in Toronto and 2015 MERS-CoV outbreak in South Korea have unveiled the critical role that hospitals play in outbreaks, especially of novel coronaviruses. Their ability to amplify the spread of disease can rapidly fuel transmission of the disease and often those failures in infection prevention and general hospital practices contribute to such events. While efforts to enhance infection prevention measures and hospital readiness are underway in the United States, it is important to understand why these programs were not able to maintain continued, sustainable levels of readiness. History has shown that infection prevention programs are primarily responsible for preparing hospitals and responding to biological events but face under-staffing and focused efforts defined by administrators. The current U.S. healthcare system though, is built upon a series of priorities that often view biopreparedness as a costly endeavor. Awareness of these competing priorities and the challenges infection prevention programs face when working to maintain biopreparedness is critical in adequately addressing this critical infrastructure in the face of an international outbreak."],"journal":"Disaster Med Public Health Prep","authors":["Popescu, Saskia"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32223774","week":"202014|Mar 30 - Apr 05","doi":"10.1017/dmp.2020.55","keywords":["biopreparedness","healthcare","hospital preparedness","infection prevention","pandemic"],"source":"PubMed","locations":["Toronto","South Korea","USA","United States"],"countries":["Canada","United States","Korea, Republic of"],"countries_codes":["CAN|Canada","USA|United States","KOR|Korea, Republic of"],"topics":["Prevention"],"weight":1,"_version_":1662819280254664706,"score":62.680984},{"pmid":32075786,"title":"Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series.","text":["Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series.","OBJECTIVE: To study the clinical characteristics of patients in Zhejiang province, China, infected with the 2019 severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) responsible for coronavirus disease 2019 (covid-2019). DESIGN: Retrospective case series. SETTING: Seven hospitals in Zhejiang province, China. PARTICIPANTS: 62 patients admitted to hospital with laboratory confirmed SARS-Cov-2 infection. Data were collected from 10 January 2020 to 26 January 2020. MAIN OUTCOME MEASURES: Clinical data, collected using a standardised case report form, such as temperature, history of exposure, incubation period. If information was not clear, the working group in Hangzhou contacted the doctor responsible for treating the patient for clarification. RESULTS: Of the 62 patients studied (median age 41 years), only one was admitted to an intensive care unit, and no patients died during the study. According to research, none of the infected patients in Zhejiang province were ever exposed to the Huanan seafood market, the original source of the virus; all studied cases were infected by human to human transmission. The most common symptoms at onset of illness were fever in 48 (77%) patients, cough in 50 (81%), expectoration in 35 (56%), headache in 21 (34%), myalgia or fatigue in 32 (52%), diarrhoea in 3 (8%), and haemoptysis in 2 (3%). Only two patients (3%) developed shortness of breath on admission. The median time from exposure to onset of illness was 4 days (interquartile range 3-5 days), and from onset of symptoms to first hospital admission was 2 (1-4) days. CONCLUSION: As of early February 2020, compared with patients initially infected with SARS-Cov-2 in Wuhan, the symptoms of patients in Zhejiang province are relatively mild.","BMJ","Xu, Xiao-Wei","Wu, Xiao-Xin","Jiang, Xian-Gao","Xu, Kai-Jin","Ying, Ling-Jun","Ma, Chun-Lian","Li, Shi-Bo","Wang, Hua-Ying","Zhang, Sheng","Gao, Hai-Nv","Sheng, Ji-Fang","Cai, Hong-Liu","Qiu, Yun-Qing","Li, Lan-Juan","32075786"],"abstract":["OBJECTIVE: To study the clinical characteristics of patients in Zhejiang province, China, infected with the 2019 severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) responsible for coronavirus disease 2019 (covid-2019). DESIGN: Retrospective case series. SETTING: Seven hospitals in Zhejiang province, China. PARTICIPANTS: 62 patients admitted to hospital with laboratory confirmed SARS-Cov-2 infection. Data were collected from 10 January 2020 to 26 January 2020. MAIN OUTCOME MEASURES: Clinical data, collected using a standardised case report form, such as temperature, history of exposure, incubation period. If information was not clear, the working group in Hangzhou contacted the doctor responsible for treating the patient for clarification. RESULTS: Of the 62 patients studied (median age 41 years), only one was admitted to an intensive care unit, and no patients died during the study. According to research, none of the infected patients in Zhejiang province were ever exposed to the Huanan seafood market, the original source of the virus; all studied cases were infected by human to human transmission. The most common symptoms at onset of illness were fever in 48 (77%) patients, cough in 50 (81%), expectoration in 35 (56%), headache in 21 (34%), myalgia or fatigue in 32 (52%), diarrhoea in 3 (8%), and haemoptysis in 2 (3%). Only two patients (3%) developed shortness of breath on admission. The median time from exposure to onset of illness was 4 days (interquartile range 3-5 days), and from onset of symptoms to first hospital admission was 2 (1-4) days. CONCLUSION: As of early February 2020, compared with patients initially infected with SARS-Cov-2 in Wuhan, the symptoms of patients in Zhejiang province are relatively mild."],"journal":"BMJ","authors":["Xu, Xiao-Wei","Wu, Xiao-Xin","Jiang, Xian-Gao","Xu, Kai-Jin","Ying, Ling-Jun","Ma, Chun-Lian","Li, Shi-Bo","Wang, Hua-Ying","Zhang, Sheng","Gao, Hai-Nv","Sheng, Ji-Fang","Cai, Hong-Liu","Qiu, Yun-Qing","Li, Lan-Juan"],"date":"2020-02-21T11:00:00Z","year":2020,"_id":"32075786","week":"20208|Feb 17 - Feb 23","doi":"10.1136/bmj.m606","link_erratum_in":"32107200","link_comment_in":"32198267","source":"PubMed","locations":["China","Zhejiang","myalgia","Huanan","Wuhan","Hangzhou"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1663095626190028800,"score":60.36558}]}